Canada markets closed

Sernova Corp. (PSH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.5180-0.0095 (-1.80%)
At close: 03:30PM CET

Sernova Corp.

The Stiller Centre
700 Collip Circle Suite 114
London, ON N6G 4X8
Canada
519 858 5184
https://www.sernova.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Frank A. Holler MBAExec. Chairman49.06kN/A1957
Dr. Philip M. Toleikis B.A., M.Sc., Ph.D.Pres, CEO & Director469.91kN/AN/A
Mr. David Swetlow C.A, C.A., CPAChief Financial Officer255.59kN/AN/A
Mr. Douglas MaretChief Science OfficerN/AN/AN/A
Mr. Christopher BarnesVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

Corporate Governance

Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.